Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma

References

• Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996; 335:865-75; PMID:8778606; http://dx.doi.org/10.1056/NEJM199609193351207.
   PubMed Web of Science ®Google Scholar
• Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004; 171:1071-76; PMID:14767273; http://dx.doi.org/10.1097/01.ju.0000110610.61545.ae.
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-34; PMID:17215530; http://dx.doi.org/10.1056/NEJMoa060655.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:16-24; PMID:16330672; http://dx.doi.org/10.1200/JCO.2005.02.2574.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28:1061-68; PMID:20100962; http://dx.doi.org/10.1200/JCO.2009.23.9764.
   PubMed Web of Science ®Google Scholar
• Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG et al. Comparative effectiveness of axitinib vs. sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011 Dec 3; 378(9807):1931-9; http://dx.doi.org/10.1016/S0140-6736(11)61613-9.
   PubMed Web of Science ®Google Scholar
• Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28(13):2144-50; PMID:20368553; http://dx.doi.org/10.1200/JCO.2009.26.7849.
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356(22):2271-81; PMID:17538086; http://dx.doi.org/10.1056/NEJMoa066838.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372(9637):449-56; PMID:18653228; http://dx.doi.org/10.1016/S0140-6736(08)61039-9.
   PubMed Web of Science ®Google Scholar
• Albiges L, Oudard S, Negrier S, Caty A, Gravis G, Joly F, Duclos B, Geoffrois L, Rolland F, Guillot A et al. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol 2012; 30(5):482-7; PMID:22231040; http://dx.doi.org/10.1200/JCO.2011.37.2516.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Aranda F, Obrist F, Eggermont A, Galon J, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: immunostimulatory cytokines in cancer therapy. Oncoimmunology 2014; 3:e29030; PMID:25083328; http://dx.doi.org/10.4161/onci.29030.
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006; 107:2409-14; PMID:16304057; http://dx.doi.org/10.1182/blood-2005-06-2399.
   PubMed Web of Science ®Google Scholar
• Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; CD001425; PMID:15674877; http://dx.doi.org/10.1002/14651858.
   PubMedGoogle Scholar
• Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol 2014; 192:5451-58; PMID:24907378; http://dx.doi.org/10.4049/jimmunol.1490019.
   PubMed Web of Science ®Google Scholar
• Tartour E, Mathiot C, Fridman WH. Current status of interleukin-2 therapy in cancer. Biomed Pharmacother 1992; 46, 473-84; PMID:1306361; http://dx.doi.org/10.1016/0753-3322(92)90005-R.
   PubMed Web of Science ®Google Scholar
• Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr Opin Immunol 2014; 27:16-25; PMID:24531241; http://dx.doi.org/10.1016/j.coi.2014.01.004.
   PubMed Web of Science ®Google Scholar
• Vesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann N Y Acad Sci 2013; 1284:1-5; PMID:23651186; http://dx.doi.org/10.1111/nyas.12105.
   PubMed Web of Science ®Google Scholar
• Gleave ME, Elhilali M, Fradet Y, Davis I, Venner P, Saad F, Klotz LH, Moore MJ, Paton V, Bajamonde A. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 1998; 338:1265-71; PMID:9562580; http://dx.doi.org/10.1056/NEJM199804303381804.
   PubMed Web of Science ®Google Scholar
• Yao J, Caballero OL, Yung WKA, Weinstein JN, Riggins GJ, Strausberg RL, Zhao Q. Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers. Cancer Immunol Res 2014; 2:371-79; PMID:24764584; http://dx.doi.org/10.1158/2326-6066.CIR-13-0088.
   PubMed Web of Science ®Google Scholar
• Linehan WM, Pinto PA, Srinivasan R, Merino M, Choyke P, Choyke L, Coleman J, Toro J, Glenn G, Vocke C et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin. Cancer Res 2007; 13:671s-79s; PMID:17255292; http://dx.doi.org/10.1158/1078-0432.CCR-06-1870.
   PubMedGoogle Scholar
• Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; 18(8):1254-61; PMID:22842478; http://dx.doi.org/10.1038/nm.2883.
   PubMedGoogle Scholar
• Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 2013; 36:133-51; PMID:23377668; http://dx.doi.org/10.1097/CJI.0b013e3182829903.
   PubMed Web of Science ®Google Scholar
• Chauvat A, Benhamouda N, Gey A, Lemoine FM, Paulie S, Carrat F, Gougeon M-L, Rozenberg F, Krivine A, Cherai M et al. Clinical validation of IFNγ/IL-10 and IFNγ/IL-2 FluoroSpot assays for the detection of Tr1 T cells and influenza vaccine monitoring in humans. Hum Vaccin Immunother 2014; 10:104-13; PMID:24084262; http://dx.doi.org/10.4161/hv.26593.
   PubMed Web of Science ®Google Scholar
• Rahma OE, Ashtar E, Ibrahim R, Toubaji A, Gause B, Herrin VE, Linehan WM, Steinberg SM, Grollman F, Grimes G et al. A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma. J Transl Med 2010; 8, 8; http://dx.doi.org/10.1186/1479-5876-8-8.
   PubMed Web of Science ®Google Scholar
• Sittig SP, Køllgaard T, Grønbæk K, Idorn M, Hennenlotter J, Stenzl A, Gouttefangeas C, Thor Straten P. Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes. Oncoimmunology 2013; 2:e26014; PMID:24228230; http://dx.doi.org/10.4161/onci.26014.
   PubMed Web of Science ®Google Scholar
• Markel G, Cohen-Sinai T, Besser MJ, Oved K, Itzhaki O, Seidman R, Fridman E, Treves AJ, Keisari Y, Dotan Z et al. Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma. Anticancer Res 2009; 29:145-54; PMID:19331144.
   PubMed Web of Science ®Google Scholar
• Remark R, Alifano M, Cremer I, Lupo A, Dieu-Nosjean M-C, Riquet M, Crozet L, Ouakrim H, Goc J, Cazes A et al. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res 2013; 19:4079-91; PMID:23785047; http://dx.doi.org/10.1158/1078-0432.CCR-12-3847.
   PubMed Web of Science ®Google Scholar
• Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M, Suzuki Y, Shintaku I, Nagura H, Ohtani H. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 2001; 61:5132-36; PMID:11431351.
   PubMed Web of Science ®Google Scholar
• Tartour E, Latour S, Mathiot C, Thiounn N, Mosseri V, Joyeux I, D'Enghien CD, Lee R, Debre B, Fridman WH. Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function. Int J Cancer 1995 63:205-12; PMID:7591205; http://dx.doi.org/10.1002/ijc.2910630210.
   PubMed Web of Science ®Google Scholar
• Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Kwon ED. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 2007b; 13:1757-61; http://dx.doi.org/10.1158/1078-0432.CCR-06-2599.
   PubMed Web of Science ®Google Scholar
• Gati A, Guerra N, Giron-Michel J, Azzarone B, Angevin E, Moretta A, Chouaib S, Caignard A. Tumor cells regulate the lytic activity of tumor-specific cytotoxic t lymphocytes by modulating the inhibitory natural killer receptor function. Cancer Res 2001; 61:3240-44; PMID:11309272.
   PubMedGoogle Scholar
• Wang QJ, Hanada K-I, Robbins PF, Li YF, Yang JC. Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma. Cancer Res 2012; 72:6119-29; PMID:23071066; http://dx.doi.org/10.1158/0008-5472.CAN-12-0588.
   PubMed Web of Science ®Google Scholar
• Dunker K, Schlaf G, Bukur J, Altermann WW, Handke D, Seliger B. Expression and regulation of non-classical HLA-G in renal cell carcinoma. Tissue Antigens 2008; 72:137-48; PMID:18721274; http://dx.doi.org/10.1111/j.1399-0039.2008.01090.x.
   PubMed Web of Science ®Google Scholar
• Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, Thompson RH, Boorjian SA, Dong H, Leibovich BC et al. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res 2008; 14:5150-57; PMID:18694993; http://dx.doi.org/10.1158/1078-0432.CCR-08-0536.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363(5):411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294.
   PubMed Web of Science ®Google Scholar
• Tartour E, Sandoval F, Bonnefoy J-Y, Fridman WH. Cancer immunotherapy: recent breakthroughs and perspectives. Med Sci (Paris) 2011; 27:833-41; PMID:22027420; http://dx.doi.org/10.1051/medsci/20112710011.
   PubMedGoogle Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144(5):646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et al. Improved survival with ipilimumab in patients with metastatic melanoma.N Engl J Med 2010; 363(8):711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466.
   PubMed Web of Science ®Google Scholar
• Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 2008; 111:3635-43; PMID:18223165; http://dx.doi.org/10.1182/blood-2007-11-123141.
   PubMed Web of Science ®Google Scholar
• Thompson RH, Dong H, Kwon ED. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res 2007a; 13:709s-15s; http://dx.doi.org/10.1158/1078-0432.CCR-06-1868.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28:3167-75; PMID:20516446; http://dx.doi.org/10.1200/JCO.2009.26.7609.
   PubMed Web of Science ®Google Scholar
• Granier C, Roussel H, De Guillebon E, Ladoire S, Gey A, Combe P, Vano Y, Fabre E, Oudard S, Badoual C, Tartour E. Biomarkers from the tumor microenvironment to predict clinical response to checkpoint inhibitors.J Oncopathol In Press. 2014.
   Google Scholar
• Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Hervé Fridman W, Cremer I, Tartour E, Zitvogel L, Kroemer G et al. Trial watch: adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2014; 3:e28344; PMID:25050207; http://dx.doi.org/10.4161/onci.28344.
   PubMed Web of Science ®Google Scholar
• Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrzewski G, Schmitt E, Dannenberg T, Lehmacher W, von Wietersheim J et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004; 363, 594-99; PMID:14987883; http://dx.doi.org/10.1016/S0140-6736(04)15590-6.
   PubMed Web of Science ®Google Scholar
• May M, Kendel F, Hoschke B, Gilfrich C, Kiessig S, Pflanz S, Seidel M, Brookman-Amissah S. Adjuvant autologous tumour cell vaccination in patients with renal cell carcinoma. Overall survival analysis with a follow-up period in excess of more than 10 years. Urologe A 2009; 48:1075-83; PMID:19562320; http://dx.doi.org/10.1007/s00120-009-2044-y.
   PubMedGoogle Scholar
• Amato RJ, Hawkins RE, Kaufman HL, Thompson JA, Tomczak P, Szczylik C, McDonald M, Eastty S, Shingler WH, de Belin J et al. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res 2010; 16:5539-47; PMID:20881001; http://dx.doi.org/10.1158/1078-0432.CCR-10-2082.
   PubMed Web of Science ®Google Scholar
• Said R, Amato RJ. Identification of pre- and post-treatment markers, clinical, and laboratory parameters associated with outcome in renal cancer patients treated with MVA-5T4. Front Oncol 2013; 3:185; PMID:23875174; http://dx.doi.org/10.3389/fonc.2013.00185.
   PubMedGoogle Scholar
• Harrop R, Treasure P, de Belin J, Kelleher M, Bolton G, Naylor S, Shingler WH. Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax). Cancer Immunol Immunother 2012; 61(12):2283-94. Epub 2012 Jun 13; http://dx.doi.org/10.1007/s00262-012-1302-9.
   PubMed Web of Science ®Google Scholar
• Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov AI, Gorelov S, Mulders P, Zielinski H, Hoos A, Teofilovici F et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 2008; 372:145-54; PMID:18602688; http://dx.doi.org/10.1016/S0140-6736(08)60697-2.
   PubMed Web of Science ®Google Scholar
• Oudard S, Rixe O, Beuselinck B, Linassier C, Banu E, Machiels J-P, Baudard M, Ringeisen F, Velu T, Lefrere-Belda M-A et al. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunol Immunother 2011; 60:261-71; PMID:21069322; http://dx.doi.org/10.1007/s00262-010-0935-9.
   PubMed Web of Science ®Google Scholar
• Amin A, Dudek A, Logan T et al. A Phase II study testing the safety and activity of AGS-003 as an immunotherapeutic in subjects with newly diagnosed advanced stage renal cell carcinoma (RCC) in combination with sunitinib. J Clin Oncol 2010; 28(15 Suppl.), Abstract: 4588.
   Google Scholar
• Amin A, Dudek A, Logan T et al. Prolonged survival with personalized immunotherapy (AGS-003) in combination with sunitinib in unfavorable risk metastatic RCC (mRCC). J Clin Oncol 2013; 31(Suppl. Six), Abstract 357.
   Google Scholar
• Draube A, Klein-González N, Mattheus S, Brillant C, Hellmich M, Engert A, von Bergwelt-Baildon M. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS ONE 2011; 6:e18801; PMID:21533099; http://dx.doi.org/10.1371/journal.pone.0018801.
   PubMed Web of Science ®Google Scholar
• Griffiths RW, Gilham DE, Dangoor A, Ramani V, Clarke NW, Stern PL, Hawkins RE. Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy. Br J Cancer 2005; 93:670-7; PMID:16222313; http://dx.doi.org/10.1038/sj.bjc.6602776.
   PubMed Web of Science ®Google Scholar
• Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 1997; 278:117-20; PMID:9311915; http://dx.doi.org/10.1126/science.278.5335.117.
   PubMed Web of Science ®Google Scholar
• Aubert S, Fauquette V, Hémon B, Lepoivre R, Briez N, Bernard D, Van Seuningen I., Leroy X, Perrais M. MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression. Cancer Res. 2009; 69:5707-15; PMID:19549898; http://dx.doi.org/10.1158/0008-5472.CAN-08-4905.
   PubMed Web of Science ®Google Scholar
• Figlin RA, Nicolette CA, Amin A et al. Monitoring T-cell responses in a Phase II study of AGS-003, an autologous dendritic cell-based therapy in patients with newly diagnosed advanced stage renal cell carcinoma in combination with sunitinib. J Clin Oncol 2011; 29(Suppl.), Abstract 2532.
   Google Scholar
• Avigan D, Rosenblatt J, Vasir B et al. Vaccination with DC/RCC fusions following cytoreductive nephrectomy. J Clin Oncol 2010; 28(15s): abstract 2511.
   Google Scholar
• Rosenblatt J, Glotzbecker B, Mills H, Vasir B, Tzachanis D, Levine JD, Joyce RM, Wellenstein K, Keefe W, Schickler M et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother 2011; 34, 409-18; PMID:21577144; http://dx.doi.org/10.1097/CJI.0b013e31821ca6ce.
   PubMed Web of Science ®Google Scholar
• Grabmaier K, A de Weijert MC, Verhaegh GW, Schalken JA, Oosterwijk E. Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene 2004; 23:5624-31; PMID:15184875; http://dx.doi.org/10.1038/sj.onc.1207764.
   PubMed Web of Science ®Google Scholar
• Birkhäuser FD, Koya RC, Neufeld C, Rampersaud EN, Lu X, Micewicz ED, Chodon T, Atefi M, Kroeger N, Chandramouli GVR et al. Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models. J Immunother 2013; 36:102-11; http://dx.doi.org/10.1097/CJI.0b013e31827bec97.
   PubMed Web of Science ®Google Scholar
• Kabbinavar FF, Zomorodian N, Belldegrun AS et al. A phase I, open label, dose escalation and cohort expansion study to evaluate the safety and immune response to autologous dendritic cells (DC) transduced with AdGMCA9 (DC-AdGMCAIX) in patients with mRCC. J Clin Oncol 2014; 32(4s): abstract 490.
   Google Scholar
• Märten A, Ziske C, Schöttker B, Renoth S, Weineck S, Buttgereit P, Schakowski F, von Rücker A, Sauerbruch T, Schmidt-Wolf IG. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother 2001; 24:502-10; http://dx.doi.org/10.1097/00002371-200111000-00007.
   PubMed Web of Science ®Google Scholar
• Wang D, Zhang B, Gao H, Ding G, Wu Q, Zhang J, Liao L, Chen H. Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer. BMC Cancer 2014; 14:251; PMID:24720900; http://dx.doi.org/10.1186/1471-2407-14-251.
   PubMed Web of Science ®Google Scholar
• Sandoval F, Terme M, Nizard M, Badoual C, Bureau M-F, Freyburger L, Clement O, Marcheteau E, Gey A, Fraisse G et al. Mucosal imprinting of vaccine-induced CD8+ T cells is crucial to inhibit the growth of mucosal tumors. Sci Transl Med 2013; 5:172ra20; PMID:23408053; http://dx.doi.org/10.1126/scitranslmed.3004888.
   PubMed Web of Science ®Google Scholar
• Adotevi O, Vingert B, Freyburger L, Shrikant P, Lone Y-C, Quintin-Colonna F, Haicheur N, Amessou M, Herbelin A, Langlade-Demoyen P et al. B subunit of Shiga toxin-based vaccines synergize with α-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity. J Immunol 2007; 179:3371-79; PMID:17709554; http://dx.doi.org/10.4049/jimmunol.179.5.3371.
   PubMedGoogle Scholar
• Fenoglio D, Traverso P, Parodi A, Tomasello L, Negrini S, Kalli F, Battaglia F, Ferrera F, Sciallero S, Murdaca G et al. A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer. Cancer Immunol. Immunother 2013; 62:1041-52; http://dx.doi.org/10.1007/s00262-013-1415-9.
   Web of Science ®Google Scholar
• Hercus TR, Thomas D, Guthridge MA, Ekert PG, King-Scott J, Parker MW, Lopez AF The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood 2009; 114:1289-98; PMID:19436055; http://dx.doi.org/10.1182/blood-2008-12-164004.
   PubMed Web of Science ®Google Scholar
• Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero MC, Mari­ani L, Parmiani G, Rivoltini L et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of mela­noma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007; 25:2546-53; PMID:17577033; http://dx.doi.org/10.1200/JCO.2006.08.5829.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:894-907; PMID:23162757; http://dx.doi.org/10.4161/onci.20931.
   PubMed Web of Science ®Google Scholar
• Salazar AM, Erlich RB, Mark A, Bhardwaj N, Herberman RB. Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial. Cancer Immunol Res 2014; 2:720-24; PMID:24801836; http://dx.doi.org/10.1158/2326-6066.CIR-14-0024.
   PubMed Web of Science ®Google Scholar
• Källberg E, Vogl T, Liberg D, Olsson A, Björk P, Wikström P, Bergh A, Roth J, Ivars F, Leanderson T. S100A9 interaction with TLR4 promotes tumor growth. PLoS ONE 2012; 7:e34207; http://dx.doi.org/10.1371/journal.pone.0034207.
   PubMed Web of Science ®Google Scholar
• Pichler M, Hutterer GC, Stoeckigt C, Chromecki TF, Stojakovic T, Golbeck S, Eberhard K, Gerger A, Mannweiler S, Pummer K et al. Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer 2013; 108:901-07; PMID:23385728; http://dx.doi.org/10.1038/bjc.2013.28.
   PubMed Web of Science ®Google Scholar
• Derhovanessian E, Adams V, Hähnel K, Groeger A, Pandha H, Ward S, Pawelec G. Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int. J. Cancer 2009; 125:1372-79; http://dx.doi.org/10.1002/ijc.24497
   Web of Science ®Google Scholar
• Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56:641-48; PMID:16960692; http://dx.doi.org/10.1007/s00262-006-0225-8.
   PubMed Web of Science ®Google Scholar
• Lutsiak MEC, Semnani RT, De Pascalis R, Kashmiri SVS, Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005; 105:2862-68; PMID:15591121; http://dx.doi.org/10.1182/blood-2004-06-2410.
   PubMed Web of Science ®Google Scholar
• Pere H, Tanchot C, Bayry J, Terme M, Taieb J, Badoual C, Adotevi O, Merillon N, Marcheteau E, Quillien VR et al. Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology 2012; 1:326-33; PMID:22737608; http://dx.doi.org/10.4161/onci.18852.
   PubMed Web of Science ®Google Scholar
• Jacobs JFM, Punt CJA, Lesterhuis WJ, Sutmuller RPM, Brouwer HM-LH, Scharenborg NM, Klasen IS, Hilbrands LB, Figdor CG, de Vries IJM et al. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clin Cancer Res 2010; 16, 5067-78; PMID:20736326; http://dx.doi.org/10.1158/1078-0432.CCR-10-1757.
   PubMed Web of Science ®Google Scholar
• Adotevi O, Pere H, Ravel P, Haicheur N, Badoual C, Merillon N, Medioni J, Peyrard S, Roncelin S, Verkarre V et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 2010; 33(9):991-8; PMID:20948437; http://dx.doi.org/10.1097/CJI.0b013e3181f4c208.
   PubMedGoogle Scholar
• Tartour E, Pere H, Maillere B, Terme M, Merillon N, Taieb J, Sandoval F, Quintin-Colonna F, Lacerda K, Karadimou A et al. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy.Cancer Metastasis Rev 2011; 30(1):83-95; PMID:21249423; http://dx.doi.org/10.1007/s10555-011-9281-4.
   PubMed Web of Science ®Google Scholar
• Bose A, Lowe DB, Rao A, Storkus WJ. Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model. Melanoma Res 2012; 22(3):236-43; PMID:22504156; http://dx.doi.org/10.1097/CMR.0b013e3283538293.
   PubMedGoogle Scholar
• Joseph RW, Parasramka M, Eckel-Passow JE, Serie D, Wu K, Jiang L, Kalari K, Thompson RH, Huu Ho T, Castle EP et al. Inverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinoma. Cancer Immunol Res 2013; 1:378-85; PMID:24778130; http://dx.doi.org/10.1158/2326-6066.CIR-13-0042.
   PubMedGoogle Scholar
• Badoual C, Combe P, Gey A, Granier C, Roussel H, De Guillebon E, Oudard S, Tartour E. Signification et intérêt clinique de l'expression de PD-1 et PDL-1 dans les tumeurs. Medecine sciences 2013a; 29:10-12; http://dx.doi.org/10.1051/medsci/2013296005.
   Web of Science ®Google Scholar
• Fourcade J, Sun Z, Pagliano O, Chauvin J-M, Sander C, Janjic B, Tarhini AA, Tawbi HA, Kirkwood JM, Moschos S et al. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8+ T cells induced by melanoma vaccines. Cancer Res 2014; 74:1045-55; PMID:24343228; http://dx.doi.org/10.1158/0008-5472.CAN-13-2908.
   PubMed Web of Science ®Google Scholar
• Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, Levionnois E, Nizard M, Si-Mohamed A, Besnier N et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013; 73:128-38; PMID:23135914; http://dx.doi.org/10.1158/0008-5472.CAN-12-2606.
   PubMed Web of Science ®Google Scholar
• Sheikh N, Petrylak D, Kantoff PW, Dela Rosa C, Stewart FP, Kuan LY et al. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother 2013; 62(1):137-47; PMID:22865266; http://dx.doi.org/10.1007/s00262-012-1317-2.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15:7412-20; PMID:19934295; http://dx.doi.org/10.1158/1078-0432.CCR-09-1624.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon R-A, Reed K et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-33; PMID:23724867; http://dx.doi.org/10.1056/NEJMoa1302369.
   PubMed Web of Science ®Google Scholar
• Schmidt SM, Schag K, Müller MR, Weinschenk T, Appel S, Schoor O, Weck MM, Grünebach F, Kanz L, Stevanovic S et al. Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis. Cancer Res 2004; 64:1164-70; PMID:14871853; http://dx.doi.org/10.1158/0008-5472.CAN-03-2538.
   PubMed Web of Science ®Google Scholar
• Sukov WR, Ketterling RP, Lager DJ, Carlson AW, Sinnwell JP, Chow GK, Jenkins RB, Cheville JC. CCND1 rearrangements and cyclin D1 overexpression in renal oncocytomas: frequency, clinicopathologic features, and utility in differentiation from chromophobe renal cell carcinoma. Hum Pathol 2009; 40:1296-1303; PMID:19386349; http://dx.doi.org/10.1016/j.humpath.2009.01.016.
   PubMedGoogle Scholar
• Saino M, Maruyama T, Sekiya T, Kayama T, Murakami Y. Inhibition of angiogenesis in human glioma cell lines by antisense RNA from the soluble guanylate cyclase genes, GUCY1A3 and GUCY1B3. Oncol Rep 2004; 12:47-52; PMID:15201957.
   PubMed Web of Science ®Google Scholar
• Salagierski M, Verhaegh GW, Jannink SA, Smit FP, Hessels D, Schalken JA. Differential expression of PCA3 and its overlapping PRUNE2 transcript in prostate cancer. Prostate 2010; 70:70-78; PMID:19760627; http://dx.doi.org/10.1002/pros.21040.
   PubMedGoogle Scholar
• Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin A-M, Figlin RA, Hutson TE, Sternberg CN, Amado RG et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 2012; 13, 827-37; PMID:22759480; http://dx.doi.org/10.1016/S1470-2045(12)70241-3.
   PubMed Web of Science ®Google Scholar
• Silini A, Ghilardi C, Figini S, Sangalli F, Fruscio R, Dahse R, Pedley RB, Giavazzi R, Bani M. Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor's proangiogenic microenvironment. Cell Mol Life Sci 2012; 69:1167-78; PMID:22130514; http://dx.doi.org/10.1007/s00018-011-0862-8.
   PubMedGoogle Scholar
• Fang YJ, Lu ZH, Wang GQ, Pan ZZ, Zhou ZW, Yun JP, Zhang MF, Wan DS. Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Colorectal Dis 2009; 24:875-84; PMID:19421758; http://dx.doi.org/10.1007/s00384-009-0725-z.
   PubMed Web of Science ®Google Scholar